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1. Introduction 
The incidence rates of End-stage renal disease (ESRD) have increased steadily 
internationally since 1989. The United States has the highest incident rate of ESRD, followed 
by Japan; Japan has the highest prevalence per million population, with the United States 
second (1). Of the 490,000 patients with ESRD in the United States, more than 380,000 are 
currently on hemodialysis (HD) (2). 
ESRD on HD disproportionately affects minority populations. Whites represent the majority 
of the HD population (59.8%), while African Americans (33.2%), Asians (3.6%), and Native 
Americans (1.6%) comprise the rest of the ESRD population. However, the incidence rate of 
ESRD among African Americans is 4-fold higher and Native Americans 2-fold higher than 
that for whites. ESRD is slightly more prevalent in men than in women (male-to-female 
ratio, 1.2:1) and more prevalent in older adults (3).   
2. Morbidity/mortality 
Chronic renal failure is associated with a very high morbidity and hospitalization rate, likely 
due to existing comorbid conditions, such as hypertension, coronary artery disease, and 
peripheral vascular disease. The first-year age-adjusted mortality rate of patients on dialysis 
is 9.4%, the two-year mortality rate is 32.3%, and the 5-year mortality rate is 60.8% (3). ESRD 
patients with diabetes have a first-year mortality rate of 23% (3). In patients with ESRD, 
cardiovascular disease is the primary cause of death, followed by sepsis and cerebrovascular 
disease. The dialysis population in the United States has a 10- to 20-fold higher risk of death 
due to cardiovascular complications than the general population after adjusting for age, 
race, and sex. The relative risk with respect to the general population is much higher in 
younger patients, with cardiovascular event rates in ESRD patients in their 20s equivalent to 
the event rates in the general population in their 80s (3). Increased understanding of the 
disease process, new insights into pathogenic mechanisms, and new therapeutic options are 
emerging that may improve survival rates and quality of life for patients with ESRD. 
3. The need for dialysis 
Given the poor outcomes for patients on HD, every effort should be undertaken to preserve 
residual renal function, which is associated with improved survival (4). Early nephrology 
referrals, patient education, and consideration of transplant options may be helpful in 
decreasing the progression to ESRD. Preparation for dialysis therapy is critical for the 
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smooth transition from CKD care to ESRD. Poor planning for initiation of dialysis is a major 
cause of increased morbidity and mortality. The use of temporary or tunneled dialysis 
catheters contributes to dialysis mortality by increasing the incidence of sepsis, acting as a 
stimulus for chronic inflammation, and damaging the central veins, thereby preventing or 
shortening the survival of more permanent vascular access once created. The chapter will 
discuss in detail regarding type of dialysis access. 
3.1 Indications for initiation of dialysis 
The appropriate time to initiate dialysis for a patient is not clearly defined. The decision to 
initiate dialysis in a patient with CKD involves the consideration of subjective and objective 
parameters by the physician and the patient. Over the past decade a trend of increasing 
estimated glomerular filtration rate (eGFR) at the initiation of dialysis for treatment of ESRD 
has been noted in the United States. In 1996, only 19% of patients began dialysis therapy 
with an eGFR of greater than 10 ml/min/1.73 m2 (denoted as 'early start'), but by 2005 the 
fraction of early start dialysis patients had risen to 45% (5). It is not known whether early 
start of dialysis is beneficial, harmful or neutral with respect to the outcome of dialysis 
treatment for ESRD (5). The timing of initiation of dialysis for ESRD is a matter of clinical 
judgment guided by values of residual renal function and symptoms and signs present in 
the patients, including those related to comorbidity. By the time the eGFR falls below 10 
ml/min/1.73 m2, most patients require dialysis. However, many patients appear to function 
quite well until the eGFR approaches 5 ml/min/1.73 m2. As a general rule, patients with 
diabetes require earlier intervention (eGFR<15 ml/min/1.73 m2) than do those with other 
etiologies for renal failure (6). Clearly, dialysis must be initiated before the uremic 
symptoms of peripheral neuropathy, encephalopathy, malnutrition, or serositis (including 
pericarditis) become evident (See Table 1). 
 
 Pericarditis or pleuritis (urgent indication)  
 Progressive uremic encephalopathy or neuropathy, with signs such as confusion, 
asterixis, myoclonus, wrist or foot drop, or, in severe cases, seizures (urgent 
indication) 
 A clinically significant bleeding diathesis attributable to uremia (urgent indication) 
 Fluid overload refractory to diuretics 
 Hypertension poorly responsive to antihypertensive medications 
 Persistent metabolic disturbances that are refractory to medical therapy; these 
include hyperkalemia, metabolic acidosis, hypercalcemia, hypocalcemia, and 
hyperphosphatemia 
 Persistent nausea and vomiting 
 Evidence of malnutrition 
Table 1. Clinical indications to initiate dialysis in patients with CKD. (7) 
3.2 ‘Early’ versus ‘Late’ dialysis 
There is conflicting evidence concerning the effect of the early initiation of dialysis on 
survival. Some retrospective and uncontrolled prospective studies have reported no 
survival benefits with early dialysis while others have found that early start of dialysis may 
be harmful (8). After a comprehensive review of the published literature by the National 
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Kidney Foundation (NKF) workgroup in 1997, they recommended that initiation of dialysis 
be considered when the arithmetic mean of the urea and creatinine clearances fell below 
approximately 10.5 ml/min/1.73 m2 except in well-nourished, asymptomatic patients (9). In 
1999 Obrador et al., observed that 23% of the US ESRD population, between 1995 and 1997, 
started dialysis at an eGFR less than 5 ml/min/1.73 m2. They opined that this 'late start' of 
dialysis needed further examination, including studies of the impact on outcomes and cost 
of ESRD treatment (10).  
In 2006, the NKF work group updated the guidelines for initiation of hemodialysis and 
stated that 'at CKD Stage 5, when the eGFR is < 15 ml/min/1.73 m2, that nephrologists 
should evaluate the benefits, risks and disadvantages of beginning renal replacement 
therapy'. They also suggested that initiation of dialysis therapy before CKD Stage 5 (an 
eGFR of > 15 ml/min/1.73 m2) may be appropriate in patients who have symptoms 
believed to be related to both their comorbidities and their level of residual kidney function 
(11). Only one study has reported the outcomes of patients with CKD who initiated dialysis 
only after the onset of symptoms due to uremia. In this prospective cohort study of 233 
consecutive patients with advanced uremia, 151 were elective starters on dialysis, while 82 
initially declined dialysis. Among the initial refusers, 55 percent developed a uremic 
emergency, while 48 percent were eventually established on maintenance dialysis. In this 
study, one year mortality was significantly higher among the initial refusers than the 
elective starters (18 versus 7 percent). However, these results are confounded by lack of 
randomization and by three deaths among the initial refusers resulting from treatment 
withdrawal (12). 
Additional published studies have not been able to demonstrate any clear-cut survival 
benefits for early start of dialysis. The only randomized controlled trial that examined 
mortality and time of dialysis initiation, the IDEAL study (13), found no difference in 
survival between early or late initiation of dialysis. In this study, 828 patients with 
progressive CKD and an estimated GFR between 10.0 and 15.0 mL/min/1.73 m2 (as 
determined by the Cockcroft-Gault equation) were randomly assigned to dialysis initiation 
when the estimated GFR was either 10 to 14 mL/min/1.73 m2 or 5 to 7 mL/min/1.73 m2. 
The median time to the initiation of dialysis was 1.8 and 7.4 months in the early and late 
start groups, respectively. At a median follow-up period of 3.6 years, the authors noted no 
significant difference in survival (38 and 37 percent mortality, hazard ratio of 1.05 with early 
initiation, 95% CI of 0.83 to 1.30) as well as no difference in cardiovascular events, infections, 
or dialysis complications between the late start group and early start group. 
However, these results do not imply that the initiation of dialysis can be delayed until the 
GFR is between 5 to 7 mL/min/1.73 m2 in all patients. The design of the IDEAL study 
permitted clinicians to initiate dialysis based upon the presence of symptoms due to uremia 
as well as on the estimated GFR. As a result, 76 percent of patients assigned to the late start 
arm initiated dialysis when the GFR was much greater than 5 to 7 mL/min/1.73 m2. This 
resulted in a mean GFR of 9.8 mL/min/1.73 m2 at the start of dialysis for the late start 
group, which was only 2.2 mL/min/1.73 m2 less than the mean start GFR for the early 
group (12.0 mL/min/1.73 m2). Thus, approximately 88 percent of all enrolled patients had 
initiated dialysis with an estimated GFR of approximately 10 mL/min/1.73 m2 or more, 
either because of symptoms or enrollment in the early dialysis arm (13). 
A recent study published in Canadian Medical Association Journal examined trends in 
initiation of hemodialysis within Canada and compared the risk of death between patients 
with early and late initiation of dialysis (14). Using the Canadian Organ Replacement 
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Registry from 2001 to 2007, the investigators identified a cohort of 25,910 patients 18 years or 
older who began hemodialysis. Dialysis was defined as beginning early if the eGFR exceeded 
10.5 mL/minute/1.73 m2. Mean eGFR at initiation of dialysis increased from 9.3 
mL/minute/1.73 m2 in 2001 to 10.2 mL/minute/1.73 m2 in 2007 (P < .001). During the same 
period, the proportion of early dialysis initiations increased from 28% (95% confidence interval 
[CI], 27% - 30%) to 36% (95% CI, 34% - 37%). Among those starting dialysis early, mean GFR at 
initiation was 15.5 mL/minute/1.73 m2 vs 7.1 mL/minute/1.73 m2 among those who started 
dialysis late. For early vs late initiation of dialysis, the unadjusted hazard ratio (HR) for death 
was 1.48 (95% CI, 1.43 - 1.54). This suggests that early initation is associated with higher 
mortality. After adjustment for demographic factors, serum albumin, primary cause of end-
stage renal disease, type of vascular access, comorbid conditions, late referral, and transplant 
status, the hazard ratio for death decreased to 1.18 (95% CI, 1.13 - 1.23). Difference in mortality 
per 1000 patient-years between starting dialysis early vs late decreased after 1 year of follow-
up but persisted and began increasing again after 24 months of follow-up, with significant 
differences at 6, 12, 30, and 36 months. (14) 
There may be two additional advantages to early dialysis: control of hypertension and 
increased dietary intake. Reversal of volume overload with dialysis often leads to a 
reduction in blood pressure, which is typically volume-dependent in CKD. Perhaps more 
important, patients on dialysis patients require at least 1 g/kg of protein per day to replace 
dialysis losses and maintain nitrogen balance. Thus, early institution of dialysis can allow a 
more liberal diet in terms of both food and fluid. 
The overall conclusion of these trials largely supports current practice that dialysis initiation 
should be based upon clinical factors rather than the estimated GFR alone. Patients with 
progressive CKD require close follow up, early nephrology referral, and adequate advance 
dialysis planning (including the presence of a functioning peritoneal or vascular access and 
referral for transplantation). Among patients with progressive CKD, clinicians must be 
vigilant for the presence of symptoms and/or signs of uremia and dialysis should be 
initiated in the patient with these symptoms. 
4. Dialysis modality selection 
Although the life expectancy of patients with end-stage renal disease has improved since the 
introduction of dialysis in the 1960s, it is still far below that of the general population. As an 
example, the mean life span at age 49 in the United States is 33 years in the general 
population but only approximately seven years in patients receiving maintenance dialysis 
(15), in whom the overall five-year survival rate is about 30 to 50 percent in nondiabetics 
(depending upon the co-morbid diagnoses) and 25 percent in diabetics (15). Despite 
improvements in technology and patient care, the mortality rate of patients on maintenance 
dialysis remains alarmingly high, at approximately 15 to 20 percent per year (16). 
There are two principal choices for maintenance dialysis: hemodialysis (HD) and peritoneal 
dialysis (PD). Selecting one of these modalities is influenced by a number of considerations 
such as availability and convenience, comorbid conditions, socioeconomic and dialysis 
center factors, the patient's home situation, method of physician reimbursement, and the 
ability to tolerate volume shifts (17-23). Most studies suggest a better survival rate in PD 
than in HD patients during the first few years after starting therapy (24). However, after 2 or 
3 years, outcome on PD becomes equal to HD, or worse (25-28). This section mainly focuses 
on different means of receiving hemodialysis. 
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The European Best Practice Guidelines for Hemodialysis recommends the standard 
hemodialysis dose should be delivered as three times per week for 4 hours each session (29). 
In an attempt to improve outcomes, it was postulated that a higher dialysis dose than 
commonly provided during conventional dialysis may increase survival among patients 
undergoing renal replacement therapies (30). 
However, this hypothesis was refuted in two large well-designed studies in both 
hemodialysis and peritoneal dialysis patients: 
- The HEMO study found that increasing the dialysis dose within the general restrictions 
of a thrice weekly regimen failed to decrease patient mortality (31). 
- In the ADEMEX study, no decrease in mortality was seen with peritoneal dialysis doses 
greater than a weekly Kt/V of 1.7 (32) 
In light of these negative studies, significant attention has turned to alternative dialysis 
schedules, such as, short-daily HD (SHD), nocturnal HD (NHD), and long, intermittent 
hemodialysis (LHD). It is suggested that more frequent dialysis may be associated an 
improvement in health-related quality of life (HRQoL) and with improved survival (33-34). 
The first successful use of short daily, or "quotidian" hemodialysis was first reported by 
DePalma in 1969 (35). This approach was based upon the premise that improved patient 
outcomes, compared with conventional three times per week hemodialysis, would occur 
with a dialysis schedule that consisted of the same number of hours of dialysis per week but 
delivered over twice as many sessions. More specifically, it involves five to seven treatments 
per week, each lasting 1.5 to 2.5 hours. The rationale for short daily hemodialysis is based 
upon a strategy that is proposed to enhance both dialysis efficiency and hemodynamic 
stability. With short daily dialysis, shortening the dialysis time while increasing the 
frequency of dialysis allows more time to be spent dialyzing against higher uremic solute 
concentration gradients. This enhances the efficiency of solute removal (36). More frequent 
dialysis allows for less interdialytic fluid accumulation. This is likely to improve 
hemodynamic stability during dialysis with increased potential for normalizing the 
extracellular fluid volume. This form of therapy has been associated with significant 
improvement in serum albumin, calcium phosphate, and volume control in small scale 
studies. However, no mortality data is available.  
A recent study, Frequent Hemodialysis Network (FHN) Daily Trial, was a multicenter, 
randomized trial that included 245 patients assigned to either frequent hemodialysis (six 
times weekly) or conventional hemodialysis. Two primary composite outcomes were 
determined at one year, including death or one-year change from baseline in left ventricular 
(LV) mass as assessed by cardiac resonance imaging, and death or one-year change in 
physical health as assessed by a RAND health survey. Both composite outcomes showed 
significant benefit to the frequent-dialysis group compared with the conventional-dialysis 
group (with hazard ratios of 0.61, 95% CI, 0.46-0.82 for death or change in LV mass; and 
0.70, 95% CI, 0.53-0.92, for death or change in physical health) (37). This study also 
demonstrated benefits in pre-determined secondary outcomes to the frequent dialysis group 
such as a decrease in LV mass, improved blood pressure control and phosphate balance but 
not on cognitive performance, depression, serum albumin concentration, or use of 
erythropoiesis-stimulating agents. 
Nocturnal hemodialysis (e.g, long nightly home hemodialysis) was introduced as a 
potentially more desirable alternative to conventional dialysis, since it provides superior 
dialysis based upon dose, duration, and frequency (38). This can be accomplished because it 
is performed during nightly sleep, an otherwise unproductive time (39).  The late Robert 
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Uldall started the first quotidian (daily) nocturnal hemodialysis program in 1994 at the 
Wellesley Hospital in Toronto (40). Since then, its use has been extended to more centers in 
Canada, the United States, Australia, and several European countries (41-44). This 
hemodialysis modality is performed five to seven times per week, with each treatment 
lasting 6 to 8 hours. Although the number of patients studied has been rather limited, but 
these evidence suggest signficant improvements in caloric intake and serum albumin 
results. 
Long intermittent hemodialysis is given three times a week and a dialysis time of 6 to 8 
hours. This procedure is practiced in Tassin, France, and has been associated with 
improvements in blood pressure control and better overall nutritional status. 
Although, no data on randomized controlled trials are available on home hemodialysis, 
some recent well-conceived cohort studies have indicated that outcome of home (daily) HD 
is superior to conventional in-centre dialysis, and even equal to cadaveric transplantation, 
when differences in case mix are taken into account (45). 
4.1 Hemofiltration and hemodiafiltration 
Hemodiafiltration is a form of chronic renal replacement therapy used most in Europe, 
particularly Germany and Belgium, and very rarely used currently in the United States (46). 
Based upon relatively better clearance of larger "middle" molecules through solvent drag, 
some claim that replacement therapy with hemodiafiltration may be superior to that with 
hemodialysis, including improved hemodynamics. 
For chronic renal replacement therapy, the two principal regimens used to provide 
substantial removal of larger MW uremic toxins via convection are intermittent 
hemofiltration (HF) and intermittent hemodiafiltration (HDF). Daily convective therapy has 
also been used. 
 Hemofiltration — With HF, fluid is removed by the dialysis machine through increased 
transmembrane pressure and the replacement solution is infused intravenously at equal 
volume minus the desired fluid volume removal. The clearance of the method for a 
particular solute is dictated by the ultrafiltration volume and the sieving coefficient. As 
the sieving coefficient for low MW unbound solutes equals 1, the clearance for small 
molecules equals the ultrafiltrate volume. Although hemofiltration is effective in the 
removal of the larger MW solutes, it is less effective in the removal of small molecules 
as it is restricted by the ultrafiltration volume. 
 Hemodiafiltration — HDF is a combination of hemodialysis and hemofiltration devised 
to overcome the low clearance of small solutes by hemofiltration by adding a diffusive 
component. 
For chronic renal replacement therapy, the standard regimen for both HF and HDF includes 
three sessions per week for three to five hours, as with conventional intermittent 
hemodialysis. A typical conservative (or high dose) regimen for HDF includes a post 
dilution configuration with a blood flow of 300 mL/min (500 mL/min for high dose), a 
dialysate flow of 500 mL/min, a flow of a substitution volume of 60 mL/min (120 mL/min 
for high dose) and a high flux dialyzer of 1.4 m2 (2.2 m2 for high dose) (47). 
Several small studies using daily HF/HDF have been published.  
 One study that addressed the short term effects of daily HF reported that predialysis 
beta-2-microglobulin levels decreased by 40 percent (48). 
 In one study in which 12 patients switched from HD to HF at home on a daily basis for 
one month, HF was associated with a lower blood pressure, higher caloric intake, and 
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improved quality of life, findings consistent with previous reports on short daily HD 
(49-50). A trend toward a decrease in serum beta-2-microglobulin could be ascribed to 
the HF alone. The infusion volume used was 40 percent of total body water, which 
offered a standard Kt/V of approximately 2.0. 
 In another study of eight patients undergoing in center daily hemodiafiltration for six 
months, there were lower serum levels of predialysis BUN and creatinine (which were 
expected by the change to a daily schedule), as well as lower levels of other solutes 
including beta-2-microglobulin and homocysteine (51). Additional benefits included 
improved phosphate control, discontinuation of all antihypertensive agents, and a 30 
percent regression in left ventricular mass. Although some of these results can be 
attributed to the daily treatment schedule, the decrease in the pretreatment levels of 
beta-2-microglobulin and the improvement in phosphate control are clearly attributable 
to both convection and the increased treatment frequency. 
4.2 Adequacy of hemodialysis 
For greater than 50 years hemodialysis (HD) has been performed in some form or another. 
Outcomes for dialysis patients expressed in terms of quality of life (QOL), mortality, and 
hospitalization, is reportedly similar to those seen in patients with solid organ cancer. 
Despite improvements in long-term outcomes demonstrated with all dialysis modalities, the 
adjusted annual mortality of dialysis patient remains high at 19% (52-53). There are many 
factors (dialysis and non-dialysis) that determines outcome. One such influential factor is 
“adequacy” of dialysis. Adequate dialysis was originally used to describe dialysis dosing 
measured by small solute removal, but is now deemed as the amount of dialysis required to 
keep a patient symptoms free, functional, with a life expectancy similar to that of healthy 
individuals. Since its inception, there have been numerous approaches to quantify the 
delivered dialysis dose in a reproducible manner, and to link the dialysis dose with clinical 
outcomes. 
4.3 Importance of urea and its use as a surrogate marker of uremic toxicity  
Solute removal during hemodialysis focuses on urea. Urea is produced from the anabolism, 
catabolism of proteins and is the principal way by which nitrogenous substances are 
excreted from the body. Urea is a small water soluble molecule (molecular weight 60 
daltons) that is slightly toxic. Recent studies have demonstrated that urea removal does not 
closely parallel that of other small water-soluble compounds, protein-bound solutes, or 
middle molecules. (54) Despite this information, adequacy of HD dosing is predominantly 
evaluated by removal of urea. During the development of the uremic syndrome, losses of 
kidney function are accompanied by deteriorating organ function attributable to the 
accumulation of uremic retention solutes or uremic toxins. (54) Uremic toxins are diverse 
and complex, they include inorganic compounds (phosphate water, potassium, water and 
trace elements), as well as organic compounds that comprises small water-soluble solutes 
(<500 d), middle molecules (>500 d), and protein-bound solutes. These peptides can be 
altered by glycosylation, oxidization or carbamylation, and they can provoke inflammation, 
hypertrophy, oxidative stress, coagulation, constriction, thus uremia is more than the 
retention and accumulation of urea or water-soluble compounds alone. (54)  Mortality has 
repeatedly been shown to be associated with the clearance of urea. Of commonly measured 
protein-derived substances, only the serum concentration of ß2-microglobulin correlates 
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with mortality. Recently, a higher free concentration of the protein-bound solute p-cresol has 
also been reported to be associated with mortality. (55) Current dialysis and dialysis-related 
treatments do not remove any significant quantity of substances larger than 10 to 15 kd. 
Future means of removing higher molecular weight toxins or protein-bound substances may 
include the use of sorbents in addition to traditional diffusive and convective dialysis 
strategies.  
4.4 Urea kinetic modeling, URR and KT/V  
The mathematical model known as urea kinetics can be used to calculate the rate of 
production and removal of urea. Measurement of the dialysis dose has, for the most part, 
relied on estimation of clearance of the small, water-soluble, and nitrogenous waste product 
urea, and hence the mathematical model is referred to as urea kinetic modeling (UKM). 
Formal (UKM) is the most accurate method for assessment of delivered dialysis dose. It 
assumes that urea is distributed in a single, well-mixed pool. UKM presumes that full 
equilibration occurs immediately between blood and tissue compartments. However, in 
vivo there is a delay in redistribution and it takes 30 to 60 minutes for equilibration between 
blood and tissue compartments post dialysis. UKM also assumes that urea is generated at a 
constant rate by protein metabolism and is removed at a constant rate by residual renal 
function, and intermittently by dialysis. Hence, in a person with negligible renal function, 
the extent of urea removal provides a measure of dialysis adequacy, and the rate of 
production correlates with dietary protein intake. (56) Thus, it’s inappropriate to follows 
predialysis blood urea nitrogen (BUN) or serum urea only; because low serum urea could be 
attributed to malnutrition (insufficient protein diet) rather than adequate dialysis urea 
removal. UKM has formed the basis for retrospective interpretation of the National 
Cooperative Dialysis Study and for prescription and control of the HEMO and the Frequent 
Hemodialysis Network studies. (60) Due its mathematical intricacy, UKM requires 
advanced computer support. UKM is the most rigorous available method for prescribing 
and evaluating dialysis dose and is widely used in the United States. Current methods for 
assessment of dialysis dose are based on the predialysis and postdialysis difference in BUN 
and include the urea reduction ratio (URR), the single-pool Kt/V (spKt/V), the equilibrated 
Kt/V (eKt/V), and the weekly standard Kt/V (std-Kt/V). 
Kt/V is a dimensionless ratio representing fractional urea clearance, where K is the dialyzer 
urea clearance (liters per hour), t is the length of HD session (hours), and V is the volume of 
distribution of urea (liters). It is the most widely used parameter to assess dialysis dose. 
Kt/V is derived from single-pool urea kinetics and is referred to as spKt/V. A value of 
spKt/V of 1 indicates that the total volume of blood completely cleared of urea during a 
dialysis session is equivalent to the volume of distribution of urea. Solute disequilibrium 
occurs when dialysis time is decreased in addition to increasing dialysis and blood flow 
rates. Solute disequilibrium can be corrected by adjusting the Kt/V for the rebound in urea, 
which happens mainly in the 30–60 minutes immediately post dialysis. The resultant Kt/V 
is termed equilibrated Kt/V or eKt/V. Numerous equations have been developed by 
Daugirdas and others to help derive the eKt/V from spKt/V.(57-59) With a conventional 4-
hour HD treatment, eKt/V is usually about 0.2 units lower than spKt/V. The difference is 
even larger with short, high-efficiency HD or hemodiafiltration, in which urea rebound is 
higher. Single-pool Kt/V or, even better, eKt/V should be assessed monthly, and dialysis 
prescription should be adapted accordingly. In large cross-sectional studies, mortality 
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increases when spKt/V falls below 1.2, and international guidelines (e.g., KDOQI) 
recommend a target spKt/V of 1.3 for a conventional dialysis schedule of three times per 
week. 
Online clearance is the term used when the dialysis dose is calculated by measuring 
conductivity or ionic clearance across the dialysis membrane. Multiple ions can be tracked at 
the same time to minimize error, and the delivered Kt/V can be predicted in real time before 
the treatment is over. Although sound in theory, the practical application is limited. UKM is 
also used to calculate the protein catabolic rate (PCR) and the protein catabolic rate 
normalized to body weight (nPCR), both of which are useful measures of nutrition. 
Urea reduction ratio (URR) is another way of quantifying the delivered dialysis dose.  
However, it’s over simplified since it does not take into account intradialytic urea generation 
and convective urea removal by ultrafiltration. Because the relative decrease in urea 
concentration during dialysis is the most significant determinant of Kt/V, direct 
measurement of URR is an accepted method for assessment of dialysis adequacy. The URR 
equation is as follows: URR = (BUNpre -BUNpost)/BUNpre where BUNpre is pre-dialysis 
urea concentration and BUNpost is post-dialysis urea concentration. By convention, the 
value is multiplied by 100 and expressed as a percentage. A minimum URR of 65% to 70% is 
recommended for adequate HD. Kt/V and URR are mathematically linked by the following 
equation: Kt/V= -ln(1-URR), where ln is the natural logarithm. (60) Accordingly, Kt/V 
equals 1.0 when URR equals 0.63 or 63% of whole-body urea has been removed. (60) 
4.5 Limitations of UKM 
One of the criticisms of UKM is the use of urea as the reference marker for measurement. 
We know that it’s a very small solute. Clearance of a solute is multifactorial; it is dependent 
on the molecular weight, charge, volume of distribution, and protein binding. Furthermore, 
clearance of solutes with different molecular weights from urea or bound to proteins would 
be different. Thus, clearance of urea cannot be extrapolated to other substances such as 
“uremic toxin” because they act differently. In addition UKM does not take into account 
residual renal function (RRF), which has a significant impact on patient outcome. (57) Also, 
it has been shown that V calculated by anthropometric formulas systematically 
overestimates volume by about 15%. (58) Kt/V underestimate that body water has an 
independent effect on outcomes, it is now recognized that smaller patients require higher 
Kt/v compared to larger patients. (61) Also, Kt/V does not confer that time (t) has an 
independent effect on outcome. The National Cooperative Dialysis (NCDS) was the first 
multicenter, randomized controlled trial of hemodialysis adequacy in which UKM was used 
to analyse the effect of BUN and HD time. Longer time was associated with better outcomes, 
however the statistical relationship between treatment time and patient outcome in was 
considered not to be significant (p value of 0.056). (61-62) Kt/V does not account for QOL, 
BP and volume control, clinically stability or biochemical factors. We know from the 
analysis of Hurricane Katrina that patients who missed three HD sessions were associated 
with odds ratio for hospitalization of 2.15. (61,63) Thus, Kt/V only measure the adequacy of 
one dialysis session, it does not incorporate missed HD sessions or shorten dialysis time.  
Some of these limitations are rectifiable.  One can increase HD time for intradialytic 
hypotension, inability to control volume, or if dialysis dosage is inadequate. HD dose can be 
based on body surface area (BSA), thus, smaller patients can receive more dialysis.   
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4.6 Hemodialysis dose  
Quantifying removal of toxic uremic solutes is important to assess the adequacy of HD. The 
delivered dialysis dose is a function of length of the session (t), dialysate and blood flow 
rates, volume of distribution (V) of the uremic toxin studied, and the dialyzer efficiency 
(KoA). Volume of distribution is very different for urea (total body water volume), than 
other small-molecular-weight. The minimum frequency and dosage of dialysis is three times 
per week, for a minimum treatment time of 3 to 4 hours, a blood flow rate of at least 250 
ml/min, and a dialysate flow rate of 500 to 800 ml/min. Patients that are initiated on HD, V 
is unknown and has to be estimated (men, 58% of body weight; women, 55% of body 
weight). After obtaining measured Kt/V the dialysis prescription can be adjusted to meet the 
Kt/V goals. For patients with severe and long-standing uremia, it’s recommended to provide 
several sessions in achieving target dose to avoid the dialysis disequilibrium syndrome. 
4.7 Recommendations for dialysis dose adequacy  
Current recommendations in the United States are as follows (KDOQI) (64):  
- A minimum spKt/V of at least 1.2 for both adult and pediatric HD patients. When URR 
is used, the delivered dose should be equivalent to a Kt/V of 1.2, that is, an average URR 
of 65%.  
- To prevent the delivered dose of HD from falling below the recommended minimum 
dose, the prescribed dose of HD should be spKt/V of 1.3, which corresponds to an 
average URR of 70%.  
- The delivered dose of HD should be measured at least once per month in all adult and 
pediatric HD patients. 
4.8 Factors affecting delivered Kt/V  
Factors that influences delivery of Kt/V is multifactorial: hematocrit, the effective dialyzer 
urea clearance Kd depends on blood and dialysate flow rates, dialyzer KoA, effective 
dialyzer surface area, anticoagulation, and recirculation. (60) Dialysis session time (t) is 
critical for reaching the Kt/V goal. Prescribe treatment time (PTT) and effective treatment 
time (ETT) may not always correlate, EET may be significantly less secondary to patient 
demand, clotting of dialyser, or  intermittent pump stops. V does not substantially change 
during a single HD session but may change over time. Dialysis dose needs to be adjusted for 
an increase in V. However, if there is a loss in body mass (weight loss, amputation of limb), 
is associated with a decrease in V, Kt/V should not be reduced but rather adjusted to the 
higher, ideal patient V or BSA. 
If faced with an inadequate delivered Kt/V, first check if that session was representative of 
an average session and no unusual problems may have occurred (e.g., shortened time 
because of patient request, needle difficulty, leaks, alarm triggering). (60) The use of 
commercial technologies that measure ionic dialysance can be implemented to monitor each 
dialysis. A frequent cause of low Kt/V is fistula integrity that causes a vascular access 
problem leading to recirculation. Blood sampling errors should be considered because 
delayed post-HD sampling will reduce Kt/V. Standardized blood sampling procedures 
should be implemented in each center. If, despite these checks, a low Kt/V remains 
unexplained, treatment time should be increased to 4.5 or 5 hours. Prescription of a more 
efficient dialyzer and higher blood and dialysate flow rates should also be considered. 
However, increasing treatment time, rather than increasing dialysate flow, or using two 
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dialysers, would be more beneficial and practical to improve adequacy. Muscle exercise 
before or during dialysis improves Kt/V by increasing blood supply to poorly perfused urea 
rich muscle tissue and thus facilitates urea equilibration. Delivered Kt/V should be checked 
whenever the dialysis prescription has been modified substantially. Online clearance 
monitoring allows assessment of Kt/V during each single session without blood sampling. 
4.9 Should volume (V) be included in Kt/V to assess target clearance?  
In an attempt to address the question of optimal dialysis dose, several clinical trial have 
proposed that patients with small urea V, such as women, do worst compared to larger 
people. This is secondary to the notion that muscle mass closely correlate to total body water 
than to body weight. Thus, small urea V is a good indicator for low muscle mass. The 
Hemodialysis Study (HEMO) was performed in which 1846 patients were randomly 
assigned to a standard or high dose of dialysis and a low- or high-flux dialyzer (based on 
clearance of beta-2-microglobulin) which revealed a beneficial effect of higher Kt/V for 
women but not for men. (65) This suggests that individuals with low muscle mass may 
require a higher clearance in relation to V and therefore raises the question of whether V is 
the appropriate denominator for dialysis dose. (60)  Native renal clearances, in contrast, are 
commonly related to body surface area (BSA), not to total body water. (60) It has been 
suggested to relate BSA to dialysis clearances. The ratio of BSA to urea V is generally higher 
in women than in men and decreases with an increment in V. Prescribing dialysis dose in 
relation to BSA (K × t/BSA) would result in more dialysis for smaller patients of either 
gender and for women of any size. (57,60) More work need to be done to validate this novel 
idea.  
4.10 Other dialysis factors related to outcomes  
There are many other factors that play a role in the outcome of dialysis adequacy. Such 
factor includes but is not restricted to middle molecule removal, hyperphosphatemia, 
preservation of RRF, vascular access, QOL and treatment time. In general, middle molecule 
removal is determined by the dialyser permeability, the presence of convection, protein 
binding, and dialysis duration. Given that daily dialysis results in more frequent solute level 
equilibration with less rebound, this technique provides higher middle molecule removal 
than with conventional hemodialysis.  The retention of solutes of middle molecular size is 
proposed to play an important role in the pathogenesis of the uremic state and contribute 
significantly to the high mortality of dialysis patients. (60) High-flux dialyzers have the 
propensity to remove larger amounts of middle molecules than low-flux dialyzers due to 
higher membrane porosity, and this may even be further increased by the use of convective 
dialysis strategies, such as hemodiafiltration. Serum β2-microglobulin, is a surrogate for 
other uremic middle molecules, is effectively removed by high-flux than by low-flux 
dialysis, and predialysis β2-microglobulin levels were found to be related to mortality in 
patients treated randomly with high-flux or low-flux dialyzers. (70) Patient who has 
diabetes on HD, or on dialysis for longer than 3.7 years, and those with serum albumin 
levels below 40 g/l, may benefit most from high-flux dialysis. (69,71) The European Best 
Practice Guidelines have recommended maximizing the removal of middle molecules in all 
dialysis patients. (60,72) 
Hyperphosphatemia is a major problem in HD and is managed by phosphate removal via 
dialysis, use of phosphate binder medication to prevent intestinal phosphate absorption 
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from dietary phosphate and dietary restriction. With the use of larger dialyzer surface area, 
hemodiafiltration, high-flux HD, removal of phosphate is significantly removal. Must 
monitor for hypophosphatemia with long frequent dialysis  
End stage renal patients initiated on dialysis initially posess considerable residual renal 
function (RRF). However, most of these patients lose their RRF by the end of the first year 
on dialysis. By year three only 10% to 20% of patients retain their RRF. RRF of 2 to 3 ml/min 
urea clearance contributes significantly to the elimination of uremic toxins. (73) The 
retention of RRF results in lower serum β2-microglobulin, phosphate, potassium, urea, 
creatinine, and uric acid levels; higher hemoglobin concentration; enhanced nutritional 
status; better quality of life scores; and a reduced need for dietary and fluid restrictions. (60) 
Left ventricular hypertrophy is associated with loss of RRF. Patient with an estimated TBW 
of 40 liters, a residual urea clearance of 2 to 3 ml/min is equivalent to a std-Kt/V of 0.5 to 
0.75/week. Dialysate water impurities, nephrotoxic agents such as radiocontrast, 
nonsteroidal anti-inflammatory drugs, aminoglycosides and activation of the immune 
system by bioincompatible membranes, intradialytic hypotension are risk factors for the loss 
of RRF. Patients who retain urine output may enhance survival augment with the regulation 
of fluid and electrolyte balance.  
5. Frequency of dialysis  
DePalma first reported in 1969 the successful use of short daily or "quotidian" hemodialysis. 
(35) Short daily dialysis (SDD) was based upon the premise that patient outcomes would 
improved, compared with conventional three times per week hemodialysis.  SDD would 
occur with a dialysis schedule that consisted of the same number of hours of dialysis per 
week but delivered over twice as many sessions. More specifically, this schedule consists of 
daily hemodialysis (five to seven days per week) provided for a duration of 1.5 to 3 or more 
hours per session. Initial attempts to popularize daily dialysis in the United States were 
suppressed by financial and logistical issues. This led to a decline in its use both in the home 
and in-center settings. However, over the last decade there has been resurgence in the use of 
daily dialysis, with several studies emerging from the United States and Europe showing 
improvements in various intermediate outcomes. Most recently, in the wake of the HEMO 
study, attention has turned from increasing the per-session dialytic dose, to altering 
variables such as treatment frequency or duration to improve outcomes (75-76) Daily 
dialysis has also been proposed as a rescue therapy and in the intensive care unit setting.  
The mortality rate of patients undergoing maintenance hemodialysis is unacceptably high. 
An extremely high morbidity, relatively low quality of life (due in part to a high level of 
dependence and unemployment), and high cost have also been observed. Contrast this with 
frequent dialysis which provides a more physiological renal replacement, because it allows 
more gentle volume removal, reduction of hemodynamic stress and better blood pressure 
control. More frequent dialysis and prolonged-duration HD have the greatest effect on 
middle molecule clearance. (74) In addition, phosphorus removal is increased secondarily to 
its predominant intracellular distribution. Protein bound solutes like p-cresol are not 
changed, because these solutes depend on RRF. The benefits of more frequent dialysis 
improve BP, thus decreasing anti-hypertensive medications, decreasing intradialytic 
hypotension, lowering serum phosphate, raising albumin and hemoglobin with lower 
requirements for erythropoiesis stimulating agents. HD patients switch to nocturnal dialysis 
improved sleep efficiency especially in stage 3 and 4 sleep with decreased in daytime fatigue 
www.intechopen.com
 
Hemodialysis Principles and Controversies 
 
239 
after 6 months. (75) Nocturnal dialysis is also associated with beneficial effects on vascular 
smooth muscle which restore the proliferation of the apoptosis ratio, which directly 
associated to serum phosphorus. However, there are no published randomized trials of 
nocturnal hemodialysis compared to other modalities. Thus studies comparing nocturnal 
hemodialysis to conventional hemodialysis should be performed to better understand the 
benefits with nocturnal hemodialysis. 
Due to the nightly schedule with nocturnal hemodialysis, the cost of consumables is higher 
than conventional hemodialysis and is similar to the cost of short daily hemodialysis. 
However, the personnel cost of nocturnal hemodialysis is lower than that with in-center 
hemodialysis regimens. (76) 
Depending upon the consumable/personnel cost ratio in different countries, nocturnal 
hemodialysis can be less or more expensive than in-center conventional hemodialysis. In 
addition, the cost of medications, including EPO, antihypertensive agents, and phosphate 
binders, is lower with nocturnal hemodialysis as well as cost of hospitalization.  
5.1 Vascular access 
Performing hemodialysis requires the ability to access and return a patient’s blood at a high 
rate. The optimal access would allow a high rate of blood flow, with no recirculation of 
dialyzed blood into the pre-dialysis blood, with maximal durability, minimal complications, 
and minimal gap from creation to use.  Currently, no hemodialysis access approaches this 
goal; each available access has shortcomings. 
The preferred access currently is the arteriovenous fistula (AVF). The AVF is created 
surgically by connecting an artery to a vein, with the subsequent increased flow and 
pressure causing the vein to “arterialize,” with thickened wall and increased size.  This 
arterialized vein can then be accessed for hemodialysis.  The advantages to the AVF are a 
high rate of blood flow with minimal recirculation, minimal complications because of the 
absence of foreign material, and an extended functional life.  The primary shortcoming of 
the AVF is the significant time from initial placement to maturation for use, which ranges 
from 25 to 98 days (81). Typically AVF is not used until 3 months after placement. However, 
a recent study of the practice patterns at dialysis facilities in DOPPS suggests that earlier 
cannulation of AVFs (even prior to 4 weeks) was not associated with increased risk of access 
failure (81). Other issues include a significant rate of primary failure of AVFs (82), vascular 
steal syndrome, inability to create AVFs because of lack of suitable vessels (82-84), and 
development of stenoses leading to AVF thrombosis and AVF failure (82-84). 
Given the significant time for their maturation, AVFs must be placed well before initiation 
of hemodialysis to avoid use of other accesses, such as tunneled catheters.  Currently, only 
15 percent of patients starting on hemodialysis use an AVF, and only 24 percent have a 
maturing AVF (85). One cause is late referral to nephrologists, but even with a timely 
referral to nephrologists, 46% of the patients did not have a permanent access placed prior 
to starting HD (85). Some barriers leading to this problem include patient resistance to 
creation of AVFs, poor access to surgeons, and decreased rate of primary patency of AVFs 
(85).  Possible solutions include improved patient education, often through patient support 
groups in CKD clinics and referral to nephrologist at earlier stage of chronic kidney disease 
(85). 
Where creation of an AVF is impossible, insertion of an arteriovenous graft (AVG) may be 
feasible. The advantage of an AVG is the high primary patency rate and minimal gap 
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between creation and first use (84,86).  Because of the presence of foreign material, there is 
increased risk of access infection, although less than that with tunneled catheters, and there 
is an increased rate of stenosis, thrombosis, and graft failure compared with AVFs. One new 
technique in the creation of AVGs is the Hemodialysis Reliable Outflow (HeROTM) dialysis 
catheter, a new FDA approved device for catheter-dependent and significant vasculopathic 
patients. The HeRO device is an AVG that extends from the arm into the right ventricle.  
This may avoid problems with stenosis at the venous anastomosis leading to graft failure.   
The third means of chronic hemodialysis access is the tunneled catheter. This catheter, like 
the standard non-tunneled dialysis catheter used for acute hemodialysis access and non-
tunneled catheters used for venous access, is inserted into a central vein, usually the internal 
jugular vein, but the risk of infection is reduced by increasing the distance between the vein 
and skin entry by running the catheter through a subcutaneous tunnel. This access has the 
advantage of being usable immediately upon insertion, but it has the highest rate of 
infection, particularly catheter-related bacteremia, and is associated with higher costs, 
morbidity, and mortality, compared with other accesses (87-88). Other complications of the 
tunneled catheter include intraluminal thrombosis and fibrin sheath. 
6. Management of access complications 
6.1 Detection and treatment of stenosis and thrombosis of AVF and AVG 
Stenosis of AVF and AVG commonly develop over time, generally resulting from response 
to endothelial damage.  This can occur at the anastamosis between native vessels or between 
a graft and a native vessel, with endothelial damage caused by surgical trauma, or distal to 
the venous anastamosis, with endothelial damage from rapid turbulent flow. If these 
stenoses are not recognized and corrected, increased access pressures and decreased flow 
can result in thrombosis of the access. Once an access has thrombosed, even if it can be 
salvaged, the duration of secondary patency is relatively short, with 62% one year patency 
average (89). Therefore, monitoring and subsequent treatment of stenosis in AVFs and 
AVGs is critical to prolonging the life of these hemodialysis accesses. For an excellent review 
of the various methods of monitoring accesses, see reference 90. There are several ways to 
monitor for stenosis. Physical exam, looking for abnormalities such as change in thrill, bruit 
or pulse, presence of arm swelling, or prolonged bleeding after dialysis, can be quite helpful 
in detecting access problems (91). Another common way to detect stenosis is with dynamic 
venous pressure monitoring. With this technique, the pressure at the venous needle is 
measured with low dialysis pump rate.  If the pressure is over 80, or if there is significant 
increase from prior pressures, there is a high likelihood of outflow stenosis (92). Measuring 
static access pressures (with blood pump off) is more accurate, and can also detect arterial 
stenoses, but this technique requires additional equipment, and is therefore not common 
(93). Another monitoring method growing in use is Doppler flow measurement.  If the flow 
decreases to less than 650 mL/minute, or if there has been significant interval decrease in 
flow, there is a high likelihood of stenosis (94). Stenoses can be detected by Doppler 
ultrasound, but the gold standard for detection and treatment of access stenosis is 
fistulogram, or the injection of contrast into the access to demonstrate visually the stenosis.  
When a fistulogram demonstrates stenosis, the stenosis can be repaired with angioplasty or 
surgical revision.  While angioplasty has a shorter secondary patency than surgical revision, 
angioplasty is generally the first line treatment of stenosis and thrombosis of AVF and AVG, 
since surgical revision can be performed after angioplasty in case of recurrent stenosis or 
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thrombosis (95). Treatment with anticoagulant or anti-platelet therapy, e.g. aspirin, 
ticlopidine or warfarin, has a modest effect on reducing stenosis and increasing patency of 
fistulas; however, this treatment is associated with increased risk of hemorrhage (96). 
Antiplatelet therapy should be a part of routine care in patient with graft but not AV fistula 
(97). Other pharmacological approaches for prevention of stenosis and patency of vascular 
access including calcium channel blocker, ACE-I and fish oil have been investigated, but 
further research is required to determine the role of these agents in maintaining fistula 
patency. 
Another complication of AVF and AVG is vascular access induced ischemia and is related to 
significant amounts of blood flow via AV fistulas. This diversion of blood via the fistula 
could cause decrease of blood flow to the distal tissue and cause ischemia (known as steal 
syndrome). It could rarely cause exacerbation of heart failure in paints with underlying 
disease. Elderly patients, patients with diabetics, peripheral vascular disease or coronary 
artery disease are at increase risk of ischemia. Pain during hemodialysis is a characteristic 
symptom.  
Another vascular access complication is central venous obstruction occurring in patients 
with previously inserted venous catheter or pacemaker placement. The rate of central 
venous obstruction is higher in patients who had their brachial venous accessed prior to 
dialysis access placement compare to patient who had internal jugular vein accessed. The 
most common clinical presentation is pain and swelling of the ipsilateral arm usually 
accompanied with the superficial collateral vein around the shoulder. Other clue for 
diagnosis of central venous obstruction is finger ulceration, pain and inadequate dialysis. 
The first option for treatment is percutaneous transluminal angioplasty and stent placement 
(angioplasty alone has a high rate of restenosis). The second option is surgical revision with 
bypass grafting and placement of HERO catheter (as discussed above).  
6.2 Catheter thrombosis and fibrin sheath formation 
One of the most common complications of hemodialysis catheters is decrease of flow or 
thrombosis.  Catheter thrombosis prevention is generally achieved through instillation of 
heparin into the catheter ports after completion of dialysis; a recent study suggests that 
weekly instillation of recombinant tissue plasminogen activator (tPA) may prevent 
thrombosis more effectively (98). Catheter thrombosis can be treated effectively by 
instillation of tPA into the catheter lumens or with exchange of the catheter over a 
guidewire; however, thrombosis frequently recurs, necessitating further procedures.  One 
cause of frequent catheter malfunction is the formation of a fibrin sheath around the tip of 
the catheter.  This can be treated with a 3 hour infusion of low-dose tPA or with mechanical 
stripping, although secondary patency rates remain low (99). 
6.3 Catheter related blood stream infection (CRBSI) 
The prevalence of central venous catheters in the United States is about 20-30% despite 
recommendations from major societies to increase the use of AV fistulas known as fistula 
first initiative. There is an increased risk of mortality with the use of catheters compared 
with the use of AV fistulas (100). This increased rate of mortality is likely related to 
infection. The rate of catheter related blood stream infection is 0.5 to 6.6 episodes per 1,000 
catheter days (101). The source of this infection is bacterial seeding from biofilms that form 
on the inside and outside of the blood stream catheter. The rate of CRBSI is directly related 
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to the species and level of virulence of the seeding bacteria. Meticulous catheter care and 
reeducation of personnel responsible for insertion of the catheters are the key elements in 
lowering the rate of catheter related infection (101). The catheter care includes but is not 
limited to sterile technique of catheter placement, exit –site care, sterile technique during 
initiation and termination of dialysis (including the use of a sterile barrier, sterile gloves, 
and antiseptic to clean the tubes) and the replacement of malfunctioning catheters over a 
guidewire (empirical administration of antibiotics does not reduce the incidence of catheter 
associated bacteremia) (102). Using standard antiseptic precautions the incidence of catheter 
related infection could drop to one episode per 1,000 catheter days which could be used to 
assess the quality of catheter care. 
The current guidelines indicate the use of tunneled cuffed catheter for long term use (more 
than 3 weeks duration) in patients in need of hemodialysis based on pathophysiological 
considerations as well as a generally lower rate of infection of tunneled, cuffed catheters 
compared to nontunneled catheters (103). The location of catheters influences the risk of 
infection. The femoral lines carry a higher rate of infection compare with the subclavian or 
jugular lines. Subsequent studies, however, only confirm an increase risk of femoral catheter 
infection in the patients with a higher BMI (87-88,102).  
Although the prophylactic use of systemic antibiotics at the time of insertion of a catheter is 
not currently recommended, the antimicrobial lock solutions for prevention of catheter 
related infection and bactremia are recommended (101). The ideal lock solution has 
anticoagulant and antimicrobial activity, is safe, and does not induce bacterial resistance. 
The antimicrobial solutions most frequently used are antibiotics or chemicals, citrate (30% 
concentrated since the lower concentration has little antimicrobial affect) (104). 
Antimicrobial lock solutions substantially reduce the risk of catheter related infection (102). 
The potential disadvantage of usage of antibiotics for antimicrobial lock solution is bacterial 
resistance and predisposition to highly resistance bacterial infection. There is also a potential 
adverse effect of these antibiotics including aminoglycoside-related ototoxicity. The 
disadvantage of usage of citrate is hypocalcemia and adverse cardiac event if the locking 
solution is pushed to the patient blood (105).  
Application of topical antibiotics to the exit site may reduce the incidence of catheter related 
infection in patients on hemodialysis. The most recent CDC guideline recommends use of 
povidone iodine antiseptic ointment or bacitracin/gramicidin/polymyxin B at the 
hemodialysis catheter exit site after each dialysis session (101). A recent Cochrane review on 
this subject concluded that the current data support only the topical application of 
mupirocin alone (among antibacterial agents) for prevention of catheter related infection 
(106). The use of antibiotic coated catheter in hemodialysis patients has not been shown to 
reduce the incidence of catheter related infection (101,107). 
Staphylococcus species in general and S. aureus in particular are among the most common 
cause of bacterial related infection.  Mortality rate is high among the patient infected with S. 
aureus (8%). Morbidity related to S. aureus is secondary to its high propensity to colonize 
prosthetic materials, heart valves, bones and joints. Nasal carriage of S. aureus is common 
among patients on dialysis, in whom it is associated with an increased risk of S. aureus 
infection. Successful elimination of S. aureus nasal carriage can be achieved by a short (5-
day) course of mupirocin applied daily to the anterior nares (108).  
Treatment of CRBSI requires systemic antibiotics and frequently discontinuation of the 
catheter and placement of temporary catheter. There are four possible options for treatment 
of CRBSI. Intravenous antibiotics alone, prompt catheter removal with delayed placement of 
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a new long term catheter, exchange of the infected catheter with a new one over guidewire, 
or use of systemic antibiotics and an antibiotic lock in the existing catheter. Antibiotic 
therapy for catheter-related infection is often initiated empirically. The initial choice of 
antibiotics will depend on the severity of the patient’s clinical disease, the risk factors for 
infection, and the likely pathogens associated with the specific intravascular device (109). 
Antibiotic therapy should be administered to patients with persistent fungemia or 
bacteremia after catheter removal (especially if the infection is caused by S. aureus). Long-
term catheters should be removed from patients with CRBSI associated with any of the 
following conditions: severe sepsis; suppurative thrombophlebitis; endocarditis; 
bloodstream infection that continues despite antimicrobial therapy to which the infecting 
microbes are susceptible (110). In uncomplicated CRBSI involving long-term catheters due 
to pathogens other than S. aureus, P. aeruginosa, fungi, because of the limited access sites in 
many patients who require long-term intravascular access for survival in hemodialysis 
patients, treatment should be attempted without catheter removal, with use of both systemic 
and antimicrobial lock therapy for 14 days and cultures should be repeated one week after 
completion of antibiotics treatment. The rate of treatment failure, however, is higher for 
patient treated with antibiotics alone (111). If the symptoms resolve after 2–3 days of 
intravenous antibiotic therapy, guidewire exchange of the catheter is associated with cure 
rates that are comparable to those associated with immediate removal and delayed 
placement of a new catheter (110). Localized Cellulites (exit site infection) should be treated 
with systemic antibiotics and exit site care. Tunnel track infection, however, requires 
catheter removal since it involves space in an area with limited vascular supply (112). 
6.4 Acute vascular access 
A large diameter venous catheter (a dual lumen venous catheter) usually placed in the 
internal jugular or femoral vein, is needed for acute or urgent hemodialysis in the absence of 
permanent vascular access. This catheter is used in patients with acute kidney injury who 
need urgent hemodialysis, in patients who need removal of a toxic agent by means of 
dialysis, or with chronic dialysis patients with a temporary inability to use a permanent 
access, as with catheter-related bacteremia. Using this type of access, one lumen of the 
venous catheter is allocated to draw blood (arterial side) and the other lumen is allocated to 
return the blood. Separation of arterial from venous lumen minimized the recirculation of 
blood during hemodialysis. Because of high risk of infection, non-tunneled femoral catheter 
should be removed within a week, while non-tunneled internal jugular catheters can be 
used for about 2 weeks. Hemodialysis catheters placed in the subclavian veins have a 
significant risk of subclavian stenosis, which can cause the arm on that side to be unsuitable 
for AVF or AVG placement, and so catheters are generally not placed in the subclavian 
veins.   An indwelling cuffed catheter is tunneled under the skin and placed in the internal 
jugular vein by an interventional nephrologist, interventional radiologist or surgeon. It is 
used when acute renal failure is expected to require hemodialysis for more than 2 weeks 
because of the decreased rate of infection (1034).  
6.5 Extracorporeal therapies in the ICU setting - continuous renal replacement 
therapy 
Critically ill, hemodynamically unstable intensive care unit (ICU) patients are typically the 
most challenging to treat with conventional dialytic modalities as described above. The 
www.intechopen.com
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
244 
intermittent volume and solute fluxes may cause significant morbidity, which includes 
worsening of hypotension and arrhythmias. Multiple modalities of renal replacement 
therapy are currently available. These include intermittent hemodialysis (IHD), continuous 
renal replacement therapies (CRRTs), and hybrid therapies, such as sustained low-efficiency 
dialysis (SLED). 
 
INDICATIONS FOR AND TIMING OF INITIATION OF DIALYSIS — Accepted 
indications for renal replacement therapy (RRT) in patients with Acute Kidney Injury 
(AKI) generally include: 
Refractory fluid overload 
Hyperkalemia (plasma potassium concentration >6.5 meq/L) refractory to medical 
therapy 
Signs of uremia, such as pericarditis, neuropathy, or an otherwise unexplained decline 
in mental status 
Metabolic acidosis (pH less than 7.1) refractory to medical therapy. 
Certain alcohol and drug intoxications 
 
CRRTs involve either dialysis (diffusion-based solute removal) or filtration (convection-
based solute and water removal) treatments that operate in a continuous mode (114-117). 
The major advantage of continuous therapy is the slower rate of solute or fluid removal per 
unit of time. Thus, CRRT is generally better tolerated than conventional therapy, since many 
of the complications of intermittent hemodialysis are related to the rapid rate of solute and 
fluid loss. It must be emphasized, however, that the protection afforded by CRRT is relative, 
not absolute. 
7. Outcomes in CRRT 
Outcomes of an increased dose of CRRT have been assessed in several randomized 
controlled trials and two meta-analyses (78-80,116-117). Conflicting results related to 
survival have been reported. To address the issue of optimal dose in CRRT and IHD, the 
United States VA/NIH Acute Renal Failure Trial Network study (ATN), the Randomized 
Evaluation of Normal versus Augmented Level of RRT study (RENAL) and two meta-
analyses were performed. All studies found that, compared with standard intensity dialysis, 
higher intensity dialysis did not result in improved survival or clinical benefits: 
In the United States VA/NIH Acute Renal Failure Trial Network study (ATN), all 1124 
patients were treated with IHD, CRRT, or SLED based upon hemodynamic status. Patients 
were randomly assigned to one of two dosing arms:  
- Intensive therapy: Hemodialysis and SLED were given six times per week and a target 
Kt/V of 1.2 to 1.4 per treatment, while CRRT was provided with an effluent flow rate of 
35 mL/kg per hour.  
- Less intensive therapy: Hemodialysis and SLED were given three times per week, while 
CRRT was provided with a flow rate of 20 mL/kg per hour.  
The death rate at day 60 was the same for both groups (53.6 percent with intensive therapy 
and 51.5 percent with less intensive therapy). In addition, the duration of renal replacement 
therapy and the rate of recovery of kidney function or nonrenal organ failure were similar 
for both treatment arms. The group that received intensive therapy had an increased 
number of hypotensive episodes. Thus, more intensive renal support beyond that obtained 
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with a standard thrice-weekly regimen (with a target Kt/V of 1.2 to 1.4 per treatment) or 
standard CRRT (with an effluent flow rate of 20 mL/kg per hour) does not improve clinical 
outcomes. 
In the RENAL study (a trial in Australia and New Zealand), 1508 patients with AKI were 
randomly assigned to CVVHDF at an effluent flow of either 25 or 40 mL/kg per hour (119). 
At 90 days, mortality was the same in each group (44.7 percent, odds ratio 1.00, 95% CI 0.31 
to 1.23). In addition, the incidence of patients who continued to receive renal replacement 
therapy at 90 days was similar with both dialysis doses (6.8 and 4.4 percent of higher and 
lower-intensity groups, odds ratio 1.59, 95% CI 0.86 to 2.92). 
Two meta-analyses, one consisting of 3841 patients and 8 trials and the other 3999 patients 
and 12 trials, found that more intense therapy did not improve survival compared with less 
intensive regimens (118-119). There was significant trial heterogeneity. 
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Hemodialysis (HD) represents the first successful long-term substitutive therapy with an artificial organ for
severe failure of a vital organ. Because HD was started many decades ago, a book on HD may not appear to
be up-to-date. Indeed, HD covers many basic and clinical aspects and this book reflects the rapid expansion of
new and controversial aspects either in the biotechnological or in the clinical field. This book revises new
technologies and therapeutic options to improve dialysis treatment of uremic patients. This book consists of
three parts: modeling, methods and technique, prognosis and complications.
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